RxDoctor Payments Data

Bushra Siddique, MD

Infectious Disease · Oklahoma City, OKNPI 1982848719

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Viiv Healthcare Company at 26.9% of the total. Reporting peaked in 2023 at $837 and has fallen 85.6% since, to $121 in 2025.

$3,348in general payments, 2019–2025

Across 181 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$901
  • Gilead$624
  • Insmed, Inc.$478
  • Merck$300
  • AbbVie$290
  • Johnson & Johnson$246
  • plus $511 from 11 others

What the payments were for

  • Food & beverage$3,341100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,348 in reported general payments places this provider in the 80th percentile of 51 infectious disease providers in Oklahoma.

See all infectious disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$10,476
Medicare patients
72
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala93$372,362
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf36$183,693
TivicayDolutegravir Sodium52$142,899
DescovyEmtricitabine/Tenofov Alafenam18$42,665
JulucaDolutegravir/Rilpivirine12$37,679
DovatoDolutegravir Sodium/Lamivudine11$32,216
Daptomycin36$30,056
ErtapenemErtapenem Sodium30$8,293
Vancomycin Hcl59$7,884
CeftriaxoneCeftriaxone Sodium33$6,163
Meropenem20$3,888
Fosfomycin Tromethamine12$3,614
MicafunginMicafungin Sodium13$3,253
Abacavir-LamivudineAbacavir Sulfate/Lamivudine11$2,833
Cephalexin82$2,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$624$415,026111 claims
Viiv Healthcare CompanyTivicay, Juluca, Dovato$901$212,79475 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 51 infectious disease providers in Oklahoma.

Other infectious disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →